BackReShape Lifesciences Overview

ReShape Lifesciences Receivables

Track ReShape Lifesciences's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
100.00% YoYΔ $-775000.00 vs prior year quarter

Peer trimmed avg / median

Loading

ReShape Lifesciences Receivables History

Loading

ReShape Lifesciences vs. peers: Receivables Comparison

Loading

ReShape Lifesciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ReShape Lifesciences (RSLS) FAQ

As of the most recent data (June 2026), RSLS shows a receivables of $0. That compares with $780K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RSLS's receivables is now $0 (was $780K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ReShape Lifesciences is outperforming or lagging.

Tracking RSLS's receivables over time shows whether ReShape Lifesciences is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $780K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has ReShape Lifesciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

ReShape Lifesciences's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.